News18»India
1-MIN READ

Bombay HC Seeks Reply from Maharashtra Govt over Plea on Easy Availability of Covid-19 Drugs

A health worker in personal protective equipment (PPE) collects a swab sample from a man as people outside wait for their test results during a rapid antigen testing check up campaign for the coronavirus disease (COVID-19), at a school in Mumbai. (Reuters)

A health worker in personal protective equipment (PPE) collects a swab sample from a man as people outside wait for their test results during a rapid antigen testing check up campaign for the coronavirus disease (COVID-19), at a school in Mumbai. (Reuters)

The plea claimed that since drugs crucial to treating COVID-19, such as Remdesivir, and an injection Actemra, are available only at select chemists, a patient loses much time in availing treatment.

Mumbai,Sep 18: The Bombay High Court on Friday directed the Maharashtra government to file a reply to a PIL seeking that drugs used to treat COVID-19 patients be made available directly at hospitals, isolation and quarantine centers where such patients were being admitted. The direction was given by a bench led by Justice K K Tated while hearing the PIL (Public Interest Litigation) filed by a local NGO, All Maharashtra Human Rights Welfare Association.

The plea claimed that since drugs crucial to treating COVID-19, such as Remdesivir, and an injection Actemra, are available only at select chemists, a patient loses much time in availing treatment. The patient’s caregivers need to “procure the drugs and also have to pay much more than the maximum retail price on many occasions,” the petitioner’s counsel, Prashant Pandey, told the HC.

Pandey said if these drugs were instead made available at hospitals or isolation centers where COVID-19 patients were being provided treatment, much time would be saved. Also, hospital staff will be able to provide patients with immediate care, he said.

The state’s counsel, Purnima Kantharia, however, sought time to file a reply. The court directed the state to file its reply by October 2.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor


Next Story
Loading...